GCA
AMAG

Gideon Capital Advisors’s AMAG Pharmaceuticals AMAG Stock Holding History

Gideon Capital Advisors’s Portfolio AMAG Stock Details AMAG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-11,725
Closed -$216K – 443
2017
Q3 		$216K Buy
+11,725
New +$219K 0.21% 239
2017
Q2 		– Sell
-14,042
Closed -$317K – 450
2017
Q1 		$317K Buy
+14,042
New +$336K 0.19% 234

Other funds holding AMAG

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Gideon Capital Advisors's AMAG Position: Q4 2017 in Review

Gideon Capital Advisors sold out of AMAG Pharmaceuticals (AMAG) in Q4 2017, closing a stake of 11,725 shares — an estimated $216K sold.

Gideon Capital Advisors first reported a position in AMAG in Q1 2017 and held it in 2 quarters. The position peaked at $317K in Q1 2017. 170 funds tracked by Wall St. Rank hold AMAG as of Q4 2017.

  • Gideon Capital Advisors reported no remaining AMAG Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Gideon Capital Advisors sold 11,725 AMAG Pharmaceuticals shares in Q4 2017, an estimated $216K.
  • Gideon Capital Advisors first reported a position in AMAG Pharmaceuticals in Q1 2017 and held it in 2 quarters.
  • Gideon Capital Advisors's AMAG Pharmaceuticals position peaked at $317K in Q1 2017.
  • 170 funds tracked by Wall St. Rank held AMAG Pharmaceuticals as of Q4 2017.

Based on Gideon Capital Advisors's 13F filing for Q4 2017, filed 14 Feb 2018.